Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma
Abstract Background Hepatitis B virus (HBV) reactivation impact negatively the prognosis of patients with HBV-related hepatocellular carcinoma (HCC). This study aimed to observe the effect of antiviral therapy (AVT) on viral reactivation and long-term outcomes after percutaneous radiofrequency ablat...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-02-01
|
| Series: | World Journal of Surgical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12957-023-02921-1 |
| _version_ | 1811165879247831040 |
|---|---|
| author | Jian Liu Hao Shen Shengyu Huang Jianbo Lin Zhenlin Yan Guojun Qian Zhenghua Lu Xuying Wan Fabiao Zhang Kui Wang Yongjie Zhang Jun Li |
| author_facet | Jian Liu Hao Shen Shengyu Huang Jianbo Lin Zhenlin Yan Guojun Qian Zhenghua Lu Xuying Wan Fabiao Zhang Kui Wang Yongjie Zhang Jun Li |
| author_sort | Jian Liu |
| collection | DOAJ |
| description | Abstract Background Hepatitis B virus (HBV) reactivation impact negatively the prognosis of patients with HBV-related hepatocellular carcinoma (HCC). This study aimed to observe the effect of antiviral therapy (AVT) on viral reactivation and long-term outcomes after percutaneous radiofrequency ablation (PRFA) for HBV-related HCC. Methods Data on 538 patients between 2009 and 2013 were reviewed. Propensity score matching (PSM) analysis was used to adjust for differences in baseline features between patients who received AVT (AVT group) and did not receive it (non-AVT group). Logistic regression was used to identify the independent factors for viral reactivation. The tumor recurrence and overall survival (OS) rates were analyzed using the Kaplan–Meier method. Recurrence patterns were also investigated. Results HBV reactivation developed in 10.8% (58/538) of patients after PRFA. AVT was associated independently with decreased viral reactivation (odd ratio: 0.061, 95% confidence interval: 0.018–0.200). In 215 pairs of patients obtained after PSM, the AVT group had lower 1-, 3-, and 5-year recurrence rates (24%, 55%, and 67% vs 33%, 75%, and 85%, respectively) and higher 1-, 3-, and 5-year OS rates (100%, 67%, and 59% vs 100%, 52%, and 42%, respectively) than non-AVT group (P < 0.001 for both). Additionally, the relapses in distant hepatic segments and the late recurrence after 2 years of PRFA were significantly reduced in the AVT group (78/215 vs 111/215 vs., P = 0.001; 39/109 vs. 61/91, P = 0.012, respectively). Conclusions AVT reduced late and distal intrahepatic recurrence and improved OS in patients undergoing PRFA for HBV-related HCC by inhibiting viral reactivation. |
| first_indexed | 2024-04-10T15:44:36Z |
| format | Article |
| id | doaj.art-c757b3d1873c427182f0bbcced381a15 |
| institution | Directory Open Access Journal |
| issn | 1477-7819 |
| language | English |
| last_indexed | 2024-04-10T15:44:36Z |
| publishDate | 2023-02-01 |
| publisher | BMC |
| record_format | Article |
| series | World Journal of Surgical Oncology |
| spelling | doaj.art-c757b3d1873c427182f0bbcced381a152023-02-12T12:13:59ZengBMCWorld Journal of Surgical Oncology1477-78192023-02-0121111110.1186/s12957-023-02921-1Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinomaJian Liu0Hao Shen1Shengyu Huang2Jianbo Lin3Zhenlin Yan4Guojun Qian5Zhenghua Lu6Xuying Wan7Fabiao Zhang8Kui Wang9Yongjie Zhang10Jun Li11Department of Hepatic Surgery, The Eastern Hepatobiliary Surgery Hospital, Naval Medical UniversityDepartment of Hepatic Surgery, The Eastern Hepatobiliary Surgery Hospital, Naval Medical UniversityDepartment of Hepatobiliary and Pancreatic Surgery, Tenth People’s Hospital of Tongji UniversityDepartment of Hepatobiliary and Pancreatic Surgery, Tenth People’s Hospital of Tongji UniversityDepartment of Hepatic Surgery, The Eastern Hepatobiliary Surgery Hospital, Naval Medical UniversityDepartment of Minimally Intervention Therapy, The Eastern Hepatobiliary Surgery Hospital, Naval Medical UniversityDepartment of Minimally Intervention Therapy, The Eastern Hepatobiliary Surgery Hospital, Naval Medical UniversityDepartment of Clinical Database, The Eastern Hepatobiliary Surgery Hospital, Naval Medical UniversityTaizhou Hospital of Zhejiang Province, Affiliated to Wenzhou Medical UniversityDepartment of Hepatic Surgery, The Eastern Hepatobiliary Surgery Hospital, Naval Medical UniversityDepartment of Biliary Surgery, The Eastern Hepatobiliary Surgery Hospital, Naval Medical UniversityDepartment of Hepatobiliary and Pancreatic Surgery, Tenth People’s Hospital of Tongji UniversityAbstract Background Hepatitis B virus (HBV) reactivation impact negatively the prognosis of patients with HBV-related hepatocellular carcinoma (HCC). This study aimed to observe the effect of antiviral therapy (AVT) on viral reactivation and long-term outcomes after percutaneous radiofrequency ablation (PRFA) for HBV-related HCC. Methods Data on 538 patients between 2009 and 2013 were reviewed. Propensity score matching (PSM) analysis was used to adjust for differences in baseline features between patients who received AVT (AVT group) and did not receive it (non-AVT group). Logistic regression was used to identify the independent factors for viral reactivation. The tumor recurrence and overall survival (OS) rates were analyzed using the Kaplan–Meier method. Recurrence patterns were also investigated. Results HBV reactivation developed in 10.8% (58/538) of patients after PRFA. AVT was associated independently with decreased viral reactivation (odd ratio: 0.061, 95% confidence interval: 0.018–0.200). In 215 pairs of patients obtained after PSM, the AVT group had lower 1-, 3-, and 5-year recurrence rates (24%, 55%, and 67% vs 33%, 75%, and 85%, respectively) and higher 1-, 3-, and 5-year OS rates (100%, 67%, and 59% vs 100%, 52%, and 42%, respectively) than non-AVT group (P < 0.001 for both). Additionally, the relapses in distant hepatic segments and the late recurrence after 2 years of PRFA were significantly reduced in the AVT group (78/215 vs 111/215 vs., P = 0.001; 39/109 vs. 61/91, P = 0.012, respectively). Conclusions AVT reduced late and distal intrahepatic recurrence and improved OS in patients undergoing PRFA for HBV-related HCC by inhibiting viral reactivation.https://doi.org/10.1186/s12957-023-02921-1Hepatocellular carcinomaRadiofrequency ablationAntiviral therapyHBV reactivationPrognosis |
| spellingShingle | Jian Liu Hao Shen Shengyu Huang Jianbo Lin Zhenlin Yan Guojun Qian Zhenghua Lu Xuying Wan Fabiao Zhang Kui Wang Yongjie Zhang Jun Li Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma World Journal of Surgical Oncology Hepatocellular carcinoma Radiofrequency ablation Antiviral therapy HBV reactivation Prognosis |
| title | Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma |
| title_full | Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma |
| title_fullStr | Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma |
| title_full_unstemmed | Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma |
| title_short | Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma |
| title_sort | antiviral therapy inhibited hbv reactivation and improved long term outcomes in patients who underwent radiofrequency ablation for hbv related hepatocellular carcinoma |
| topic | Hepatocellular carcinoma Radiofrequency ablation Antiviral therapy HBV reactivation Prognosis |
| url | https://doi.org/10.1186/s12957-023-02921-1 |
| work_keys_str_mv | AT jianliu antiviraltherapyinhibitedhbvreactivationandimprovedlongtermoutcomesinpatientswhounderwentradiofrequencyablationforhbvrelatedhepatocellularcarcinoma AT haoshen antiviraltherapyinhibitedhbvreactivationandimprovedlongtermoutcomesinpatientswhounderwentradiofrequencyablationforhbvrelatedhepatocellularcarcinoma AT shengyuhuang antiviraltherapyinhibitedhbvreactivationandimprovedlongtermoutcomesinpatientswhounderwentradiofrequencyablationforhbvrelatedhepatocellularcarcinoma AT jianbolin antiviraltherapyinhibitedhbvreactivationandimprovedlongtermoutcomesinpatientswhounderwentradiofrequencyablationforhbvrelatedhepatocellularcarcinoma AT zhenlinyan antiviraltherapyinhibitedhbvreactivationandimprovedlongtermoutcomesinpatientswhounderwentradiofrequencyablationforhbvrelatedhepatocellularcarcinoma AT guojunqian antiviraltherapyinhibitedhbvreactivationandimprovedlongtermoutcomesinpatientswhounderwentradiofrequencyablationforhbvrelatedhepatocellularcarcinoma AT zhenghualu antiviraltherapyinhibitedhbvreactivationandimprovedlongtermoutcomesinpatientswhounderwentradiofrequencyablationforhbvrelatedhepatocellularcarcinoma AT xuyingwan antiviraltherapyinhibitedhbvreactivationandimprovedlongtermoutcomesinpatientswhounderwentradiofrequencyablationforhbvrelatedhepatocellularcarcinoma AT fabiaozhang antiviraltherapyinhibitedhbvreactivationandimprovedlongtermoutcomesinpatientswhounderwentradiofrequencyablationforhbvrelatedhepatocellularcarcinoma AT kuiwang antiviraltherapyinhibitedhbvreactivationandimprovedlongtermoutcomesinpatientswhounderwentradiofrequencyablationforhbvrelatedhepatocellularcarcinoma AT yongjiezhang antiviraltherapyinhibitedhbvreactivationandimprovedlongtermoutcomesinpatientswhounderwentradiofrequencyablationforhbvrelatedhepatocellularcarcinoma AT junli antiviraltherapyinhibitedhbvreactivationandimprovedlongtermoutcomesinpatientswhounderwentradiofrequencyablationforhbvrelatedhepatocellularcarcinoma |